GRIEVANCES OF FIRMS AGAINST TER OF THE FRAMEWORK CONTRACT FOR THE PROCUREMENT OF DRUGS/MEDICINES (FINANCIAL YEAR 2026-27)

Inq.	Generic Name	Offered Specifications	Quoted Brand Name /strength/pack size/ volume/dosage form	Company Name/ Manufactured by	Obtained marks	Document Evaluation Remarks	Physical Verification of claims and Remarks (Compliant/non-compliant)	Final Status	Grievance of the Firm	Decision of GRC
22	**Permethrin 5% lotion**	Plaveo Lotion 5%, Bottle of 60ml. Individually packed in carton. The instructions for uses/side effects etc. should be printed on the outer carton. Rate will be calculated on per ml basis DML: 000785 DRC: 076508	5% 1s 60ml Lotion	Hiranis Pharmaceuticals (pvt) Ltd	43	1. Gel Clindacure (Batch# B0198) declared adulterated by DTL Bahawalpur vide TRA No.01-10096009075 /DTL. dated 30-jun-2026	1. The firm claimed that they are manufacturing plaveo lotion in liquid section (mouth wash) in which they have two sub-sections, 1. for oral liquids 2. mouth wash but the firm has not approval from DRAP under GMP certificate, further firm stated that the GMP Inspection is planned for GMP certificate update. However, according to physical verification of	Non-Responsive	With due respect, we wish to submit this grievance against the non-responsive status assigned to our firm following the inspection conducted on 09 October 2026. We respectfully submit the following clarifications for your kind consideration. l) Manufacturing Area and Equipment for Plaveo Lotion Please note that at the time of opening meeting on audit day	Mr. Mukaram from M/s Hiranis Pharmaceuticals (pvt) Ltd attended the meeting. It was noted that the grievance of the firm was found to be uploaded on Punjab E-Procurement system on **26.10.2026**. The Technical Evaluation report was uploaded on **21.10.2026**. As per Rule 67 of PPR, 2014, the grievance was required to be uploaded on e-Procurement Systems within **05 days;** i.e., till **25-10-2026**. Hence, the grievance is time barred. The committee further examined the grievance of the firm in the light of Advertised Evaluation Criteria and

GRIEVANCES OF FIRMS AGAINST TER OF THE FRAMEWORK CONTRACT FOR THE PROCUREMENT OF DRUGS/MEDICINES (FINANCIAL YEAR 2026-27)

							area and BMRs of Lotion, it was verified that firm is manufacuring all creams, lotions and gels in same semisolid section particularly BMR of Plaveo Lotion Batch No. B1177 manufacturing date Oct-2026 and Clindacure 1% Gel Batch No. B0340 Manufacturing date 04-2026 was prepared in semisolid manufacturing area. There was only one pnematic pump available in the semisolid quarantine area for the purpose of transfer of all the products. Additionally,		dated 09/10/2026, DGHS Inspection team discussed the matter of section used for manufacturing of "Plaveo Lotion", during discussion it was briefed about its manufacturing in "Mouthwash Section" but in dedicated manufacturing Tank. Since Mouthwashes are generally classified as Topical Liquids for external use only and not meant to be swallowed same like Topical Lotions therefore manufacturing the two in same area do not harm	specifications along with Technical Evaluation Report. The committee after due deliberation decided as under: 1.Gel Clindacure (Batch# B0198) declared adulterated by DTL Bahawalpur vide TRA No.01-10096009075/DTL. dated 30-jun-2026 2. The claim of the firm regarding manufacturing of plaveo lotion in mouth wash section was not accepted. 3. The firm itself admitted that GC-MS/FID or LC-MS and Climatic chamber were not available and FTIR was not CFR compliant. **Hence, grievance of the firm was not accepted and the status of the quoted**

GRIEVANCES OF FIRMS AGAINST TER OF THE FRAMEWORK CONTRACT FOR THE PROCUREMENT OF DRUGS/MEDICINES (FINANCIAL YEAR 2026-27)

							there was only one functional filling line for all the products and there was no separation for oral liquids, gels, creams and lotion. The firm showed another filling line for semisolids (also labelled as Liquid filling 2) but that line was found non-functional as its components were scattered in various places. It was observed that the line was non-functional as under installation tag was there and pressure differential gauge was also not installed at		the overall decorum of both dosage forms. However, for more precautious and to justify the GMP standards both Of the dosage forms are manufactured in completely different, exclusively designated tanks. During Physical Inspection team witnessed the semi solids manufacturing section and checked that Semi Solids Manufacturing kettles were present in the area for manufacturing Of Gel/Cream and Ointments,	**item remained Non-Responsive.**

GRIEVANCES OF FIRMS AGAINST TER OF THE FRAMEWORK CONTRACT FOR THE PROCUREMENT OF DRUGS/MEDICINES (FINANCIAL YEAR 2026-27)

							this area. Further there was no logbook/record regarding utilization of that filling line. 2. GC-MS/FID or LC-MS and Climatic chamber were not available. 3. FTIR was available but not CFR compliant.		whereas in "Mouthwash Section" manufacturing tanks were present for manufacturing of Lotion. In physical inspection, our two products namely Clindacure 1% gel Batch NO. B0340 and Plaveo Lotion batch No. BI 177 has been mentioned With manufacturing in Semi Solids Manufacturing. It is stated that Clindacure 1% gel Batch NO. B0340, being semi solids was manufactured in said section, whereas Plaveo Lotion batch NO.	

GRIEVANCES OF FIRMS AGAINST TER OF THE FRAMEWORK CONTRACT FOR THE PROCUREMENT OF DRUGS/MEDICINES (FINANCIAL YEAR 2026-27)

									Bl 177 (1000 liters batch size) was not manufactured in Semi Solids Section, however upon review of BMR, typographic mistake was noted, as few batches With 1000 liters batch size (non-routine batch size) were manufactured so typographic error remains unnoticed. Routine batch size of Plaveo Lotion is 1500 liters and more than hundreds batches have been manufactured since Jan-2023. Furthermore, please note that we had applied	

GRIEVANCES OF FIRMS AGAINST TER OF THE FRAMEWORK CONTRACT FOR THE PROCUREMENT OF DRUGS/MEDICINES (FINANCIAL YEAR 2026-27)

									in "Licensing Division" Of DRAP Islamabad for renaming Of "Mouthwash Section" as "Mouthwash / Lotion Section". Please also note that during physical inspection we informed that we have dedicated filling machines for Lotion, Mouthwash and Oral Liquids, as Multiple Nozzle filling machine, single nozzle filling machine and double nozzle filling machine, We also informed that one more multiple nozzle filling machine is under	

GRIEVANCES OF FIRMS AGAINST TER OF THE FRAMEWORK CONTRACT FOR THE PROCUREMENT OF DRUGS/MEDICINES (FINANCIAL YEAR 2026-27)

									installation. The same witnessed by the team and mentioned in the report. It is also worth mentioning that we have 04 different Pneumatic pumps used for transfer Of Lotion, Mouthwash, Oral Liquids and semi solid products. 2) Please note that we have 06 stability chambers for conducting stability studies, however reference standards are kept in cool incubator for temperature control, additionally	

GRIEVANCES OF FIRMS AGAINST TER OF THE FRAMEWORK CONTRACT FOR THE PROCUREMENT OF DRUGS/MEDICINES (FINANCIAL YEAR 2026-27)

									placed in desiccator for humidity control. 3) Request for Reconsideration In view of the above clarifications, we respectfully request that the inspection observations and the non-responsive Status assigned to our firm be reconsidered on the basis Of the available documentary evidence. We are Willing to provide any additional records or clarification required by the competent authority. We therefore	

GRIEVANCES OF FIRMS AGAINST TER OF THE FRAMEWORK CONTRACT FOR THE PROCUREMENT OF DRUGS/MEDICINES (FINANCIAL YEAR 2026-27)

									humbly request that, upon satisfactory verification Of the submitted evidence and fulfillment Of applicable regulatory requirements, our firm may kindly be declared RESPONSIVE. 'We assure your esteemed office Of our full cooperation and continued commitment to GMP compliance.	
6	**Dobutamine HCl 250mg Injection**	Tobuject 250mg/20ml, vial of 20ml, Pack of 1's, packed in carton with leaflet DML: 000801 DRC: 094025	Tobuject 250mg/20ml 1's 20ml Injection	MTI Medical (Pvt.) Ltd	53	Injection Vinvin (Batch # VI-012) declared adulterated by DTL Rawalpindi vide TRA	Compliant	Non-Responsive	With reference to the Technical Evaluation Report for Framework Contract for Procurement of Drugs/Medicines FY 2026-27 for	Mst. Areeba Shahid from M/s MTI attended the meeting. It was noted that the grievance of M/s MTI was found to be uploaded on Punjab e-Procurement System on **28.10.2026** at 12.05

GRIEVANCES OF FIRMS AGAINST TER OF THE FRAMEWORK CONTRACT FOR THE PROCUREMENT OF DRUGS/MEDICINES (FINANCIAL YEAR 2026-27)

						No. 01-75007529.			Inquiry no. 06, we respectfully submit this grievance against the declaration of Tobuject Injection 250mg (Dobutamine), as non-responsive. The product has been declared non-responsive based on the observation of Vinvin Batch No. VI-012 Declared Adulterated by DTL Rawalpindi for which our justification is as follows: The product declared adulterated pertains to a lyophilized injectable powder, whereas the quoted	pm whereas, the Technical Evaluation report was uploaded on **21.10.2026**. As per Rule 67 of PPR, 2014, the grievance was required to be uploaded on e-Procurement System within **05 days;** i.e., till **25-10-2026.** **Hence, the grievance is time barred.** The committee heard the viewpoint of the firm as adulterated injection is manufactured in lyophilized powder section and quoted item is manufactured in liquid injectable section as both manufacturing sections are independent. Hence, the grievance of the firm **was accepted to the extent of this parameter. However, the status of**

GRIEVANCES OF FIRMS AGAINST TER OF THE FRAMEWORK CONTRACT FOR THE PROCUREMENT OF DRUGS/MEDICINES (FINANCIAL YEAR 2026-27)

									product, Tobuject Injection 250mg/20ml, is a liquid injectable formulation. Both formulations are manufactured in separate dedicated areas within our facility. Liquid injectables are manufactured on the ground floor, while the adulterated batch of Vinvin VI-012 lyophilized injectable was manufactured on the second floor, with separate manufacturing arrangements and controls. Further, no liquid	**the firm remained Non-Responsive as the grievance is time barred.**

GRIEVANCES OF FIRMS AGAINST TER OF THE FRAMEWORK CONTRACT FOR THE PROCUREMENT OF DRUGS/MEDICINES (FINANCIAL YEAR 2026-27)

									injectable product manufactured at our facility has ever been declared adulterated by any DTL in Pakistan. The same stance was placed before the grievance committee in Directorate General Health Services Phase I Tender (DGHS) and the grievance was accepted. Screenshot attached as reference. Therefore, we humbly request that the observation related to a lyophilized product may not be linked with	

GRIEVANCES OF FIRMS AGAINST TER OF THE FRAMEWORK CONTRACT FOR THE PROCUREMENT OF DRUGS/MEDICINES (FINANCIAL YEAR 2026-27)

									the quoted liquid injectable product and Tobuject Injection 250mg/20ml may kindly be reconsidered and declared responsive. In view of the above, we respectfully request reconsideration of the evaluation observations and declaration of Tobuject Injection 250mg/20ml as technically responsive.	
33	**Sodium Phosphate (Enema) Solution**	Kleen Enema Monobasic Sodium Phosphate 16gm, Dibasic Sodium phosphate 6gm, Bottle of 135ml,	Kleen Enema 16gm+6gm 1s 135mL Liquid Enema	Nabi Qasim Industries (Pvt.) Ltd	43		Potentionometer was not available for finished product testing of Kleen enema.	Non-Responsive	"We applied for the Framework Contract with the under mentioned items of our company, enclosing all the pre-requisites	Mr. Asim from M/s Nabi Qasim Industries (Pvt.) Ltd attended the meeting. The committee examined the grievance in the light of Advertised Evaluation Criteria and

GRIEVANCES OF FIRMS AGAINST TER OF THE FRAMEWORK CONTRACT FOR THE PROCUREMENT OF DRUGS/MEDICINES (FINANCIAL YEAR 2026-27)

		Enema Bottle with Nozzle, Individually Packed in carton with leaflet Mfg. Lic. No: 000105 Drug Reg. No: 006715							required for the purpose, and our facility was subjected to physical verification by the technical evaluation team. It has been noticed through the above referred Technical Evaluation Report that both of our items have been declared Non-Responsive, with 43 marks obtained out of 67, solely on the remark that a Potentiometer was not available for finished product testing. Details are as under:- ITEM NO. 33 (Monobasic	specifications along with Technical Evaluation Report. The committee after due deliberation decided as under: 1. The committee heard the stance of the firm regarding purchase of potentiometer and observed that purchase order is post-dated i.e., after physical inspection which cannot be accepted being generated document rather than historical. The stance of the firm regarding observation of physical verification committee during verification of claims, “Potentiometer was not available for finished product testing of Kleen enema” was not

GRIEVANCES OF FIRMS AGAINST TER OF THE FRAMEWORK CONTRACT FOR THE PROCUREMENT OF DRUGS/MEDICINES (FINANCIAL YEAR 2026-27)

									Sodium Phosphate 16gm + Dibasic Sodium Phosphate 6gm Enema - Brand: Kleen Enema, Drug Reg. No. 006715) Report remark: ""Potentiometer was not available for finished product testing of Kleen enema."" At the time of inspection we had already provided the quotation for the Potentiometer, and its purchase was in process. The Potentiometer has now been purchased and installed in our QC laboratory (invoice, installation and	accepted to the extent of this parameter. **Hence, the status of the quoted item remained Non Responsive.**
34	**Clotrimazole 1% skin cream**	Dermosporin 20gm Skin Cream. Clotrimazole 1% skin cream, tube of 20g, packed in carton with lealflet. Rate will be decided on per gram basis. Mfg. Lic. No: 000105 Drug Reg. No: 008505	Dermosporin1% 1s 20gm Cream	Nabi Qasim Industries (Pvt.) Ltd	43		The firm did not have 50-mL screw-capped centrifuge tube as required by USP. Further, centrifuge machine for 50 ml centrifuge tube was also not available for finished product testing	Non-Responsive		The committee heard the stance of the firm regarding purchase of 50-mL screw-capped centrifuge tube and machine for 50 ml centrifuge tube and observed that purchase order is post-dated i.e., after physical inspection which cannot be accepted being generated document rather than historical. The stance of the firm regarding observation of physical verification committee during verification of claims:- “The firm did not have 50-mL screw-capped centrifuge tube as

GRIEVANCES OF FIRMS AGAINST TER OF THE FRAMEWORK CONTRACT FOR THE PROCUREMENT OF DRUGS/MEDICINES (FINANCIAL YEAR 2026-27)

									calibration record attached). Please revalidate. ITEM NO. 34 (Clotrimazole 1% Skin Cream, 20gm - Brand: Dermosporin, Drug Reg.No. 008505) Report remark: "The firm did not have 50-mL screw-capped centrifuge tube as required by USP. Further, centrifuge machine for 50 ml centrifuge tube was also not available for finished product testing. "The centrifuge has now been purchased 50-mL screw-capped centrifuge tube	required by USP. Further, centrifuge machine for 50 ml centrifuge tube was also not available for finished product testing". It was not accepted to the extent of these parameters. **Hence, the status of the quoted item remained Non-Responsive.**

GRIEVANCES OF FIRMS AGAINST TER OF THE FRAMEWORK CONTRACT FOR THE PROCUREMENT OF DRUGS/MEDICINES (FINANCIAL YEAR 2026-27)

									as required by USP and installed. Please revalidate In the light of the above, we respectfully submit that the deficiency noted against our items has been fully rectified. The Potentiometer and centrifuge is now installed and functional, and our laboratory is ready for re-verification at the earliest convenience of the Committee. It is therefore requested that the Committee may kindly (i) arrange re-verification of the installed Potentiometer	

GRIEVANCES OF FIRMS AGAINST TER OF THE FRAMEWORK CONTRACT FOR THE PROCUREMENT OF DRUGS/MEDICINES (FINANCIAL YEAR 2026-27)

									and centrifuge, and (ii) declare our items Item No. 33 and Item No. 34 as Responsive, for healthy competition and in the best interest of the needy public. Your cooperation in this regard will be much appreciated."	
29	**Oxytocin 5IU/ml Injection**	Syntomax 5 IU / ml Injection, Glass ampoule, pack of 50's, packed in carton with leaflet. DML No. 000124 DRC No. 083007	Syntomax 5 IU 5 IU / ml 50's 1ml Injection	Indus Pharma	41	1. Undertaking clause 5 (i) was not as per criteria & (ii) Mfg equipment list not attached 2. Claimed shelf life calculated from Mfg & Exp date mentioned on	Compliant	Non-Responsive	With reference of above said Tender we are non-responsive due to following reasons: 1. Undertaking Clause 5 (i) was not as per criteria. 2. MFG. Equipment list not attached. 3. Claim Shelf Life not as per	Rana Adil from M/s Indus Pharma attended the meeting. The committee examined the grievance in the light of Advertised Evaluation Criteria and specifications along with Technical Evaluation Report. The committee after due deliberation decided as under:

GRIEVANCES OF FIRMS AGAINST TER OF THE FRAMEWORK CONTRACT FOR THE PROCUREMENT OF DRUGS/MEDICINES (FINANCIAL YEAR 2026-27)

						samples is 18 months which differs to the one mentioned on DRC i.e. 24months			DRC. We are enclosed herewith all following documents: 1.Undertaking. 2. MFG. Equipment list. 3. Undertaking regarding Shelf Life. In the light of the above, you are requested to kindly accept our Grievance and declare our Quoted Item ar Responsive in the interest of fair and healthy competition. **Justification for Short Expiry of Syntomax Injection 5 IU (Reg. No. 083007)** Dear Sir, Due to unforeseen supply-chain	1. The firm submitted the undertaking as per statement mentioned in clause 5 (i) and Manufacturing Equipment list as per the Clause (ii) of the evaluation criteria, which was **accepted.** 2. The committee heard the stance of firm regarding Shelf life on submitted sample. As the shelf life of samples falls within the limits mentioned on DRC of quoted product and the firm furnished undertaking that the stock will be provided as per the shelf life mentioned on the DRC issued vide no No.F.3 -10/2016-Reg-II(M-263) dated 18th December,2016 of product, which was accepted. **Hence, the grievance of firm was accepted**

GRIEVANCES OF FIRMS AGAINST TER OF THE FRAMEWORK CONTRACT FOR THE PROCUREMENT OF DRUGS/MEDICINES (FINANCIAL YEAR 2026-27)

									disruptions and delays in the availability of essential raw materials and other manufacturing components, production of the subject injectable products was delayed despite the prior procurement of pre-printed ampoules bearing the expiry date and batch no Consequently, the remaining shelf life of the finished products was reduced. This reduction resulted solely from the delay in production and the expiry date	**to the extent of these parameters.** Hence, the status of the quoted item changed to **Responsive.**

GRIEVANCES OF FIRMS AGAINST TER OF THE FRAMEWORK CONTRACT FOR THE PROCUREMENT OF DRUGS/MEDICINES (FINANCIAL YEAR 2026-27)

									already printed on the packaging materials. We respectfully request the Tender Committee to consider these circumstances while evaluating our submission. Furthermore, we hereby undertake to supply the order with a shelf life of two (02) years, as documented in the Product Registration Letter, subject to applicable regulatory requirements.	

MOM OF GREIVANCE REDRESSAL COMMITTEE AGAINST TECHNICAL EVALUATION REPORT OF FRAMEWORK CONTRACT FOR THE PROCUREMENT OF MEDICAL DEVICES etc. FOR FY 2026-27

Inq. No.	Generic Name	Bidder / Importer / Sole Agent	Quoted Brand/ Manufactured by/ Key Specifications	Obtained Marks	Document Evaluation Remarks (Where Non-Compliance)	Physical Verification of Claims (Compliant/ Non-Compliant)	Final Status (Responsive/ non-responsive)	Grievance of the firm	Decision of GRC
1	Blood Bags Sterile Packs 450/500ml single	IBL Healthcare Limited	WEGO MDIR-0000002 ELI-00119 Shandong Weigao Group Medical Polymer Limited, China WEGO Blood Bag size 500ml sterile (single blood bag) master carton 100	35	1. Address of the firm on Establisment registration certificate is not as per the enlistment certificate. 2. Address of the firm on Sale License is not as per the enlistment certificate. 3. Sole Agency Agreement for the quoted item verified either by the Pakistan embassy in the country of origin or by the embassy of the country of origin in Pakistan or certified through apostille not attached. 4. Address of the firm on sole agency agreement is not as per the enlistment certificate. 5. Address of the firm on submitted sample is not as per the enlistment certificate.	Compliant	Non-Responsive	Respected Madam/sir, I. Introduction and admissibility M/S IBL Healthcare Limited (IBL) offered WEGO single sterile blood bags, 450/500 ml, manufactured by Shandong Weigao Group, China, against Inquiry No. I. Bids were submitted and opened on II August 2026. The Technical Evaluation Committee (TEC) declared the bid non responsive on nine documentary observations in the Technical Evaluation Report (TER) announced on 21st October, 2026. This grievance is lodged under Rule 67 of the Punjab Procurement Rules 2014 (the Rules) on 25th October, 2026, within five days of that announcement as Rule 67 requires, before any procurement contract has come into force.	Mr. Nouman Aslam Butt, representative of M/s IBL Healthcare Limited attended the meeting. It was noted that the grievance of firm was uploaded on Punjab e-Procurement system on **26.10.2026** and the Technical Evaluation Report was uploaded on **21.10.2026**. As per Rule 67 of PPR-2014 the grievance was required to be uploaded within 05 days i.e., till **25-10-2026**. Hence the grievance of the firm cannot be entertained being **time-barred**. However, the committee examined the grievance of the firm in the light of Advertised Evaluation Criteria and specifications along with Technical Evaluation Report. The committee after due deliberation decided as under:

MOM OF GREIVANCE REDRESSAL COMMITTEE AGAINST TECHNICAL EVALUATION REPORT OF FRAMEWORK CONTRACT FOR THE PROCUREMENT OF MEDICAL DEVICES etc. FOR FY 2026-27

					6. Address of manufacturer on ISO 13485 certification is not as per the enlistment certificate. 7. Address of manufacturer on Quality Compliance Standards of quoted item is not as per the enlistment certificate. 8. Brand name of quoted product not mentioned on attached Registration of foreign manufacturer. 9. Name and Address of foreign manufacturer on attached Registration of foreign manufacturer with regulatory authority of the country of manufacturer for the quoted product not verified.			**Grievance of M/s WIRHA & CO against M/s IBL Healthcare Limited:** H. MATERIAL INCONSISTENCIES AND DEFICIENCIES CONCERNING M/S IBL HEALTHCARE LIMITED (QUOTED BRAND: WEGO) – UNMATCHED MANUFACTURER DETAILS, UNVERIFIED CE EXTENSION, AND INAPPLICABLE FREE SALE CERTIFICATE: i. Inconsistent Manufacturer Details & Unverified CE Extension: The bidder failed to reconcile the particulars of the manufacturer appearing across its bid documents, CE Certificate, and product labels. The claimed extension of the CE Certificate was completely unsupported by any official endorsement, letter, or confirmation from a designated Notified Body. For a Class C sterile medical device, discrepancies in manufacturing identity and address represent fundamental defects rather than clerical errors.	1. For point 1,2,4 and 5 the representative of the firm presented his stance that the discrepancies in the addresses of the firm were attributable to a change in the name of Avenue only. However, on perusal of the documents, the Committee observed that the addresses mentioned on the Establishment Registration Certificate, Drug Sale License, Sole Agency Agreement and submitted sample, i.e., **Section A, 2nd Floor, One IBL Centre, Plot No. 1, Block 7 & 8, DMCHS, Tipu Sultan Road, Off Shahrah-e-Faisal, Karachi**, and **Godown: Plot No. 56, Sector 7/A, KIMZ, Karachi**, were different from those mentioned on the Enlistment Certificate, i.e., **First Floor, N.I.C.L. Building, Abbasi Shaheed Road, Karachi**, and **Godown: F-2Q, PTC Factory, SITE, Karachi**. Accordingly, the firm could not satisfy the GRC. So the

MOM OF GREIVANCE REDRESSAL COMMITTEE AGAINST TECHNICAL EVALUATION REPORT OF FRAMEWORK CONTRACT FOR THE PROCUREMENT OF MEDICAL DEVICES etc. FOR FY 2026-27

								ii. Inapplicable Free Sale Certificate Issued to Different Corporate Entity: The Free Sale Certificate submitted by the firm was issued in the name of distinct entity (Shandong Weigao Blood Transfusion Products Co. Ltd.) rather than the declared manufacturer (Shandong Weigao Group Medical Polymer Co. Ltd.). No corporate group structure, manufacturing agreement, or official endorsement was placed on record to establish the legal nexus, rendering the certificate inapplicable to the quoted blood bags. iii. Licensing and Registration Discrepancies: The firm's Establishment Registration Certificate, Sale License, and Sole Agency Agreement carried addresses that were not in conformity with the Enlistment Certificate, rendering the bid non-compliant with compulsory knockdown requirements. iv. The M/S IBL does not have valid and apostle sole agency	grievance of the firm to the extent of this parameter was **rejected.** 2. The sole agency agreement submitted by the firm was not verified either by the Pakistan embassy in the country of origin or by the embassy of the country of origin in Pakistan or certified through apostille. Hence, the grievance of the firm to the extent of this parameter was **rejected.** 3. Regarding point 6,7 and 9 the Committee noted that the address of the manufacturer mentioned on the ISO 13485 Certification (Quality Compliance Standard) did not correspond with the address mentioned on the Enlistment Certificate. Hence, the grievance of the firm to the extent of this parameter was **rejected.** 4. Regarding Points 8 and 9, the Committee observed that, upon verification of the foreign registration of the

								agreement, rendering the bid noncompliant with compulsory knockdown requirements. **Grievance of M/s Genome Pharma against M/s IBL Healthcare Limited:** 1. The firm does not have the required duly verified or apostilled Sole Agency Agreement for the quoted item. 2. The manufacturer's address on the sample does not match the address stated in the enlistment certificate. 3. The manufacturer's address on the ISO 13485 certificate does not match the address stated in the enlistment certificate. 4. The manufacturer's address on the quality certificate does not match the address stated in the enlistment certificate. 5. The foreign manufacturer's name on the registration certificate does not match the name stated in the enlistment certificate.	quoted product, the registration records reflected a change in the manufacturer's name and/or address in 2023. However, the manufacturer's name/ address mentioned in the documents submitted by the firm did not correspond with the updated particulars reflected in the registration records. The firm failed to furnish any documentary evidence or establishing the consistency of the particulars across the submitted documents despite given sufficient time. Furthermore, the brand name of the quoted product was not mentioned on the submitted foreign registration certificate. Hence, the grievance of the firm to the extent of this parameter was **rejected.** **Hence, grievance of the firm was not accepted and the status of the quoted item remained Non-Responsive.**

MOM OF GREIVANCE REDRESSAL COMMITTEE AGAINST TECHNICAL EVALUATION REPORT OF FRAMEWORK CONTRACT FOR THE PROCUREMENT OF MEDICAL DEVICES etc. FOR FY 2026-27

									Grievance of M/s WIRHA & CO against M/s IBL Healthcare Limited: Representatives of M/s IBL Healthcare and M/s WIRHA & CO Pvt. Limited attended the meeting. Grievance redressal committee heard the both parties at length and it was noted that grievance of M/s IBL Healthcare was already rejected. So, there is no Locus Standi to proceed the grievance of M/s WIRHA & CO Pvt. Limited against M/s IBL Healthcare **Grievance of M/s Genome Pharma against M/s IBL Healthcare Limited:** Representatives of M/s IBL Healthcare and M/s Genome Pharma Pvt. Limited attended the meeting. Grievance redressal committee heard the both parties at length and it was noted that grievance of M/s IBL Healthcare was already rejected. So, there is no Locus Standi to proceed the grievance of M/s Genome

MOM OF GREIVANCE REDRESSAL COMMITTEE AGAINST TECHNICAL EVALUATION REPORT OF FRAMEWORK CONTRACT FOR THE PROCUREMENT OF MEDICAL DEVICES etc. FOR FY 2026-27

									Pharma Pvt. Limited against M/s IBL Healthcare.
1	Blood Bags Sterile Packs 450/500ml single	Genome Pharma	DEMOTEK MDIR-0003576 ELI-00267 Demophorius limited Cyprus. Blood Bag size 450ml sterile (single blood bag), master carton of 100.	28	1. Registration of foreign manufacturer with regulatory authority of the country of manufacturer for the quoted product duly verifiable by the issuing authority not attached. 2. The attached Goods Declaration certificates and import documents indicate import of stock from China instead of the quoted source i.e., Cyprus.	Compliant	Non-Responsive	It is respectfully submitted on behalf of M/s Genome Pharma that certain aspects of the technical evaluation and the assessment of bidder's submitted documents require reconsideration. We request the Grievance Redressal Committee to review the matters below objectively and strictly in accordance with the tender requirements and applicable rules. A. Grievances of M/s Genome Pharma 1. Clarification Regarding Manufacturing Sources of Demotek Blood Bags (China and Cyprus) M/s Genome Pharma imports Demotek Blood Bags from both China and Cyprus. The products are manufactured by the same manufacturer and have identical product specifications. Relevant Goods Declarations (GDs) for imports from both China and Cyprus	Mr. Haris Sher from M/s Genome Pharma Pvt Limited appeared before the GRC. It was noted that the grievance of M/s Genome Pharma was uploaded on Punjab e-Procurement system on **26.10.2026** and the technical evaluation report was uploaded on **21.10.2026**. As per Rule 67 of PPR, 2014, the grievance was required to be uploaded within 05 days i.e., till **25-10-2026**. Hence the grievance of the firm cannot be entertained being **time-barred**. The committee examined the grievance of the firm in the light of Advertised Evaluation Criteria and specifications along with Technical Evaluation Report. The committee after due deliberation decided as under: 1. The firm's stance regarding Goods Declaration Certificates and import documents indicating import of stock from China was not

MOM OF GREIVANCE REDRESSAL COMMITTEE AGAINST TECHNICAL EVALUATION REPORT OF FRAMEWORK CONTRACT FOR THE PROCUREMENT OF MEDICAL DEVICES etc. FOR FY 2026-27

								have been submitted with our tender documents. Different public-sector institutions may require import documentation reflecting different supply routes. We therefore submitted GDs from both countries to provide complete documentary evidence. Although importing through Cyprus is comparatively more expensive than importing through China, the documents were submitted to demonstrate the authenticity of our imports and the availability of the same product through both channels. We respectfully request that the GDs and supporting documents relating to both sources be thoroughly reviewed and considered, and that our firm not be disadvantaged merely because the same product has been imported through two different sources.	accepted, as the country of origin mentioned by the bidder is Cyprus. Hence, grievance of the firm was not accepted to the extent of this parameter. 2. The firm furnished the documents regarding registration of foreign manufacturer with regulatory authority of the country of manufacturer for the quoted product duly verifiable by the issuing authority, which were accepted. Hence, grievance of the firm was accepted to the extent of this parameter. 3. The committee perused the attached documents regarding public sector sales experience and observed that the import documents attached along with purchase orders indicate import of supplied stock from China instead of the quoted source i.e., Cyprus. The company could not substantiate its stance regarding Experience Marks for Public-Sector Sales and no marks were awarded to the extent of this parameter.

MOM OF GREIVANCE REDRESSAL COMMITTEE AGAINST TECHNICAL EVALUATION REPORT OF FRAMEWORK CONTRACT FOR THE PROCUREMENT OF MEDICAL DEVICES etc. FOR FY 2026-27

								2. Clarification Regarding Certification Requirements for the Cyprus Manufacturer The quoted Demotek Blood Bags are manufactured in Cyprus. As per our understanding of the applicable regulatory requirements, the Free Sale Certificate is the relevant certificate for the product in question. A duly notarized and apostilled Free Sale Certificate has been submitted at pages 19–21 of our tender documents. We request that the submitted certificate be examined and assessed in accordance with the applicable regulatory requirements and the specific provisions of the tender, without imposing any additional certification requirement not stipulated in the bidding documents. 3. Request for Reconsideration of Experience Marks for Public-Sector Sales The tender evaluation criteria provide marks for experience	**Hence, the grievance of the firm was liable to be rejected and the status of the quoted item remained non-responsive.** **Grievance of M/s Wirha & Co Against M/s Genome Pharma:** Representatives of M/s Genome Pharma and M/s WIRHA & CO Pvt. Limited appeared before the Grievance redressal committee and they were heard at length. It was noted that grievance of M/s Genome Pharma was already rejected. So, there is no Locus Standi to proceed the grievance of M/s WIRHA & CO Pvt. Limited against Genome Pharma.

MOM OF GREIVANCE REDRESSAL COMMITTEE AGAINST TECHNICAL EVALUATION REPORT OF FRAMEWORK CONTRACT FOR THE PROCUREMENT OF MEDICAL DEVICES etc. FOR FY 2026-27

								in the sale of the quoted products to public-sector institutions since 01 July 2024. The criteria require purchase orders for the quoted items, along with delivery challans/payment proof, corresponding standard DTL reports, and supporting import and shipping documents, including bills of lading/air waybills, commercial invoices and packing lists verifiable through WeBOC/PSW. M/s Genome Pharma has submitted relevant purchase orders and supporting experience documents, including the corresponding DTL reports, from page 117 onward. However, no marks have been awarded under this criterion. We request that the documents from page 117 onward be checked against each stipulated requirement and, if found compliant, the appropriate marks be awarded in accordance with the tender evaluation criteria.	

MOM OF GREIVANCE REDRESSAL COMMITTEE AGAINST TECHNICAL EVALUATION REPORT OF FRAMEWORK CONTRACT FOR THE PROCUREMENT OF MEDICAL DEVICES etc. FOR FY 2026-27

								Grievance of M/s Wirha & Co Against M/s Genome Pharma: FATAL DISCREPANCIES AND REGULATORY VIOLATIONS CONCERNING M/S ALPHA EVOLUTION ENTERPRISES (QUOTED BRAND: DEMOTEK) – UNDECLARED CHINESE SOURCE, CANCELED CE CERTIFICATE, AND ABSENCE OF MDR i. TRANSITION EVIDENCE: Country of Origin & Undeclared Manufacturing Facility: The bidder claimed Cyprus (Demophorius Limited) as the manufacturing source in its regulatory/enlistment papers. However, actual import Goods Declarations (GDs) and shipping documents established that the blood bags were manufactured and imported from an undeclared facility in China (Jiaxing Tianhe Pharmaceutical Co. Ltd.). This Chinese facility is neither declared on the DRAP Registration Certificate, nor identified on the product labels, nor backed by any verifiable corporate link.	

MOM OF GREIVANCE REDRESSAL COMMITTEE AGAINST TECHNICAL EVALUATION REPORT OF FRAMEWORK CONTRACT FOR THE PROCUREMENT OF MEDICAL DEVICES etc. FOR FY 2026-27

								Sourcing a Class C life-saving blood transfusion device from an undeclared and uninspected Chinese manufacturer constitutes an incurable violation of Section 17 of the Medical Devices Rules, 2017 and mandatory traceability norms. ii. Canceled CE Certificate & Unlawful Reliance on QMS Certificate: The previously relied upon EC certificate from Notified Body TÜV SÜD was canceled approximately one year prior to its expiration without any successor certification. In its place, the firm submitted a general QMS / ISO 13485 certificate, which only attests to management systems and cannot substitute for product-specific CE certification for Class C devices. iii. Lack of Notified Body Scope under MDR Code MDN 1212: The Notified Body (HT-Cert) medical relied upon by the firm lacks designated scope in the official NANDO database for blood bags and blood	

MOM OF GREIVANCE REDRESSAL COMMITTEE AGAINST TECHNICAL EVALUATION REPORT OF FRAMEWORK CONTRACT FOR THE PROCUREMENT OF MEDICAL DEVICES etc. FOR FY 2026-27

								collection systems under MDR Code MDN 1212. Furthermore, the bidder failed to produce any formal application, signed written agreement, or Notified Body confirmation letter required under Regulation (EU) 2023/607 to claim the MDR transition extension period. Consequently, their bid is non-responsive on compulsory knockdown parameters.	
1	Blood Bags Sterile Packs 450/500ml single	WIRHA & CO	NCS MDIR: 0007924 ELI: 01261 Suzhou Laishi Transfusion Equipment Co and China ""Blood Bag size 500ml sterile (single blood bag), master carton of 100 or less.	19	1. Sole Agency Agreement for the quoted item verified either by the Pakistan embassy in the country of origin or by the embassy of the country of origin in Pakistan or certified through apostille not attached. 2. Manufacturer's Address on submitted sample is not as per the enlistment certificate. 3. Manufacturer's Address on online verifiable ISO 13485 is not as per the enlistment certificate. 4. Manufacturer's Address on online verifiable Quality	Compliant	Non-Responsive	1. That the Applicant / Aggrieved Bidder, M/s Wirha & Co., is a legally established firm registered with the Federal Board of Revenue (Active Taxpayer on both Sales Tax and Income Tax Lists) and the Punjab Procurement Regulatory Authority (PPRA). The Applicant is an accredited vendor engaged in the importation, distribution, and lawful supply of quality medical devices, consumables, reagents, and hospital equipment throughout Pakistan, possessing valid Establishment Registration and Sales Licenses issued by the	Mr. Waqas from M/s Wirha & Co appeared before the GRC. The committee examined the grievance of the firm in the light of Advertised Evaluation Criteria and specifications along with Technical Evaluation Report. The committee after due deliberation decided as under: 1. The representative of the firm presented document regarding sole agency agreement in its grievance. However, the committee after perusing the documents observed that address of the firm on submitted document was

MOM OF GREIVANCE REDRESSAL COMMITTEE AGAINST TECHNICAL EVALUATION REPORT OF FRAMEWORK CONTRACT FOR THE PROCUREMENT OF MEDICAL DEVICES etc. FOR FY 2026-27

					certificate is not as per the enlistment certificate. 5.Name of foreign manufacturer on attached Registration of foreign manufacturer with regulatory authority of the country of manufacturer for the quoted product not as per the enlistment certificate. 6. Firm did not obtain qualifying marks for quoted item.			Drug Regulatory Authority of Pakistan (DRAP) and the Provincial Quality Control Board. 2. That the Procuring Agency invited competitive sealed bids under the Punjab Procurement Rules, 2014 for the Framework Contract for the Procurement of Medical Devices etc. (FY 2026–27, Phase-III), with the statutory cut-off and bid submission/opening date fixed as 11th August, 2026 (11-08-2026). The Applicant submitted its bid in strict adherence to all statutory, codal, and technical parameters for Inquiry No. 1: Blood Bags Sterile Packs 450/500ml Single (Offered Brand: NCS; Foreign Manufacturer: M/s Suzhou Laishi Transfusion Equipment Co., Ltd., China; MDIR: 0007924; ELI: 01261). 3. That upon announcement of the Technical Evaluation Report, the Applicant was astonished to observe that despite complying with all mandatory knockout criteria	different from the address mentioned on the Enlistment Certificate and it was not apostille/notarized. Hence, the stance of the firm was not accepted and no additional marks were given against this parameter. 2. Manufacturer's Address on submitted sample is not as per the enlistment certificate. 3. Address of manufacturer on ISO 13485 certification, Quality Compliance Standard was not as per the enlistment certificate 4. Upon verification of foreign registration of quoted product, it was observed that the certificate indicated a change in the manufacturer’s name, which is different from the quoted manufacturer. The name of firm on submitted document was **Suzhou RAAS Blood transfusion Equipment Co., Ltd** which is different from quoted manufacturer i.e., **Suzhou Laishi Blood**

MOM OF GREIVANCE REDRESSAL COMMITTEE AGAINST TECHNICAL EVALUATION REPORT OF FRAMEWORK CONTRACT FOR THE PROCUREMENT OF MEDICAL DEVICES etc. FOR FY 2026-27

								and furnishing complete documentary dossiers, the Technical Evaluation Committee (TEC) erroneously declared the Applicant 'Non-Responsive', awarding merely 19 marks out of 45. This determination is predicated upon an omission of submitted private sector experience certificates, mechanical disregard of the multi-year sole agency relationship (wrongly depriving the Applicant of 11 marks), and an untenable misconstruction of post-tender municipal address updates of the foreign principal that occurred strictly after the bid submission date of 11-08-2026, completely ignoring the dual manufacturing sites already duly audited and declared in the DRAP master registration dossier. 4. That simultaneously, the competing bidders in the same category suffer from fatal and incurable technical, legal, and regulatory non-compliances under the Medical Devices	**transfusion Equipment Co., Ltd.** The firm failed to provide any supporting document regarding this change of name. 5. The firm submitted private sale summary However, the committee after perusing the documents found that the submitted documents do not provide sufficient evidence to establish that firm has achieved the mandatory requirement of 50% private sale in Punjab. So, no additional marks were given against this parameter. **Hence, grievance of the firm was not accepted and the status of the quoted item remained non-responsive.** **Grievance of M/s Genome Pharma against M/s Wirha $ Co:** Representatives of M/s Wirha & Co and M/s Genome Pharma Pvt. Limited, appeared before the Grievance Redressal Committee and they were heard at length. It was noted that grievance of M/s Wirha &

MOM OF GREIVANCE REDRESSAL COMMITTEE AGAINST TECHNICAL EVALUATION REPORT OF FRAMEWORK CONTRACT FOR THE PROCUREMENT OF MEDICAL DEVICES etc. FOR FY 2026-27

								Rules, 2017 and mandatory bidding criteria, which legally disentitle them from consideration. 5. That being severely aggrieved, the Applicant submits this representation for rectification of its own evaluation and formal determination on the following explicit grounds: GROUNDS I. LEGAL AND FACTUAL GROUNDS CONCERNING M/S WIRHA & CO. (ENTITLEMENT TO MARKS AND TECHNICAL RESPONSIVENESS) A. ARBITRARY OMISSION AND WRONGFUL DENIAL OF 03 MARKS FOR RELEVANT EXPERIENCE IN THE PRIVATE SECTOR DESPITE FULL ATTACHMENT IN BID: i. That under the advertised Technical Evaluation Matrix for Medical Devices, specific marks are demarcated for past sales performance of the quoted item in the Private Sector: 03 Marks.	Co was already rejected. So, there is no Locus Standi to proceed the grievance of M/s Genome Pharma against Wirha & Co.

MOM OF GREIVANCE REDRESSAL COMMITTEE AGAINST TECHNICAL EVALUATION REPORT OF FRAMEWORK CONTRACT FOR THE PROCUREMENT OF MEDICAL DEVICES etc. FOR FY 2026-27

								ii. That the Technical Evaluation Committee has assigned zero (0) marks under this evaluation head, alleging non-compliance or failure to satisfy the parameter. iii. That this finding is entirely contrary to the actual physical and electronic record submitted in the Applicant's bid dossier. The Applicant specifically enclosed, indexed, and flagged authentic Purchase Orders, commercial supply agreements, verified delivery challans, and satisfactory performance certificates for blood collection bags supplied to reputable private sector healthcare institutions, hospitals, and blood transfusion centers across Pakistan. iv. That despite the unequivocal physical attachment and presentation of complete Private Sector sales records, the Technical Evaluation Committee mechanically omitted to evaluate them. This arbitrary	

MOM OF GREIVANCE REDRESSAL COMMITTEE AGAINST TECHNICAL EVALUATION REPORT OF FRAMEWORK CONTRACT FOR THE PROCUREMENT OF MEDICAL DEVICES etc. FOR FY 2026-27

								withholding of 03 legitimate marks constitutes an error on the face of the record and violates Rule 4 of the Punjab Procurement Rules, 2014, which mandates fair, transparent, and non-discriminatory scrutiny. B. UNLAWFUL WITHHOLDING OF 08 MARKS FOR SOLE AGENCY / BIDDER-MANUFACTURER RELATIONSHIP (ABOVE 2 TO 5 YEARS): i. That under the evaluation matrix under the heading 'Bidder & Manufacturer Relationship', the scoring criteria provides: Up to 2 Years (05 Marks); Above 2 to 5 Years (08 Marks); and Above 5 Years (10 Marks). ii. That the Applicant has maintained an active, continuous, and legally unbroken sole agency relationship with the principal manufacturer, M/s Suzhou Laishi Transfusion Equipment Co., Ltd., China, spanning over	

MOM OF GREIVANCE REDRESSAL COMMITTEE AGAINST TECHNICAL EVALUATION REPORT OF FRAMEWORK CONTRACT FOR THE PROCUREMENT OF MEDICAL DEVICES etc. FOR FY 2026-27

								four (04) consecutive years, strictly falling in the bracket of 'Above 2 to 5 Years' entitled to 08 marks. iii. That complete historic agency contracts, manufacturer authorization agreements, and chronological import clearance documents (Goods Declaration GDs) proving uninterrupted commercial representation were duly submitted in the bid dossier. Withholding these 08 marks is completely unlawful and prejudicial. iv. That regarding Remark No. 1 (Sole Agency Agreement verified by Pakistan Embassy / Apostille not attached), it is submitted that the authentic authorization executed by the manufacturer is fully notarized, valid, and legally binding under applicable commercial treaties. Denying legitimate relationship marks while the vendor relationship is established by contemporaneous official	

								records is contrary to law and justice. C. TECHNICAL AND LEGAL STATUS OF DUAL MANUFACTURING SITES (TONGLI TOWN & MINHANG DISTRICT, SHANGHAI, VALIDITY AS ON CUT-OFF DATE (11-08-2026), POST-TENDER ADMINISTRATIVE UPDATES, AND AVAILABILITY OF FRESH TÜV NOTIFIED BODY APOSTILLED CREDENTIALS: i. That Remark Nos. 2, 3, 4, and 5 of the Evaluation Report allege that the manufacturer's address on the submitted sample, online verifiable ISO 13485, and Quality Certificate does not match the DRAP Enlistment Certificate. ii. That the aforesaid adverse remarks proceed upon a fundamental misconstruction of facts and an acute disregard of the statutory regulatory framework: a) Recognized Dual Manufacturing Facilities in DRAP Master Dossier: It is an	

								established, audited fact on regulatory record that the foreign principal, M/s Suzhou Laishi Transfusion Equipment Co., Ltd., operates recognized dual manufacturing facilities:1. Changsen Road, Tongli Town, Wujiang District, Suzhou, Jiangsu Province, China; AND 2. No. 500 Youdong Road, Minhang District, 201100 Shanghai, P.R. China. Both these manufacturing facilities were already formally disclosed, documented, and audited within the master DRAP registration dossier. The ISO 13485, CE certification, and Free Sale Certificates have consistently covered and named these facilities, ensuring that the regulatory certification fully mirrors the officially recognized manufacturing sites. b) Status Prevailing on Tender Submission Date (11-08-2026): On the statutory cut-off date of tender submission and opening (11th August,	

MOM OF GREIVANCE REDRESSAL COMMITTEE AGAINST TECHNICAL EVALUATION REPORT OF FRAMEWORK CONTRACT FOR THE PROCUREMENT OF MEDICAL DEVICES etc. FOR FY 2026-27

								2026), the ISO 13485 certificate, Quality Compliance Certificate, and DRAP Enlistment Certificate (ELI: 01261 / MDIR: 0007924) submitted in the technical bid dossier were 100% active, legally valid, fully authentic, and perfectly aligned with the Changsen Road, Tongli Town and Minhang District, Shanghai premises. At that date, every single document inside the bid was unchallengeable, contemporaneous, and fully operative. c) Subsequent Post-Tender Municipal Re-Numbering (Post 11-08-2026): Strictly subsequent to 11th August, 2026, the local municipal government authorities executed an administrative zoning re-organization and re-numbering of the industrial sector. This was purely an external municipal address change without any physical relocation of production machinery, cleanrooms, sterilization	

MOM OF GREIVANCE REDRESSAL COMMITTEE AGAINST TECHNICAL EVALUATION REPORT OF FRAMEWORK CONTRACT FOR THE PROCUREMENT OF MEDICAL DEVICES etc. FOR FY 2026-27

								facilities, or technical personnel. d) Issuance of Fresh ISO 13485, CE by Notified Body TÜV, and Apostilled Documents on Updated Address: In strict compliance with regulatory standards following the post-11-08-2026 municipal update, the internationally recognized Notified Body TUV conducted the necessary conformity assessments and issued a renewed ISO 13485 certificate and updated CE Certificate reflecting the revised municipal address designation. Likewise, a fresh Sole Agency Agreement was executed. The Applicant has already secured complete international legal attestation: the newly issued ISO 13485, the updated CE Certificate issued by TÜV, and the renewed Sole Agency Agreement on the updated address have all been fully Notarized and Apostilled under the Hague Apostille Convention.	

MOM OF GREIVANCE REDRESSAL COMMITTEE AGAINST TECHNICAL EVALUATION REPORT OF FRAMEWORK CONTRACT FOR THE PROCUREMENT OF MEDICAL DEVICES etc. FOR FY 2026-27

								e) Technical Explanation of Online Verification Portal: When the Technical Evaluation Committee conducted online verification weeks/months after tender opening, the online accreditation database was naturally displaying the newly updated certificate and latest municipal address issued by TÜV. The Committee erroneously applied this post-tender online status retrospectively against the Enlistment Certificate, failing to appreciate that on the tender opening date (11-08-2026), the submitted ISO certificate on Changsen Road, Tongli Town / Youdong Road, Minhang District, Shanghai was 100% valid and operative. iii. That under settled public procurement jurisprudence affirmed by the Superior Courts of Pakistan, the responsiveness of a bidder must be evaluated strictly with reference to the status prevailing on the cut-off date of	

								bid submission (11-08-2026). A subsequent administrative address re-designation post-tender cannot be applied retrospectively to disqualify a responsive bid—particularly when the dual manufacturing sites are fully documented in the DRAP dossier, and fresh TÜV-notified, Apostilled certificates establish seamless regulatory continuity. D. FORMAL SUBMISSION OF POST-LICENSING VARIATION (PLV) BEFORE DRAP – AT FINAL DECISION STAGE: i. That to maintain complete statutory harmony between the foreign principal's municipal address re-designation and the local regulatory records, the Applicant proactively filed a formal Post-Licensing Variation (PLV) application before the Medical Device Division of the Drug Regulatory Authority of Pakistan (DRAP) pursuant to Rule 17 of the Medical Devices Rules, 2017.	

MOM OF GREIVANCE REDRESSAL COMMITTEE AGAINST TECHNICAL EVALUATION REPORT OF FRAMEWORK CONTRACT FOR THE PROCUREMENT OF MEDICAL DEVICES etc. FOR FY 2026-27

								ii. That the said PLV application has successfully crossed all preliminary verifications, passed rigorous technical scrutiny, and has already reached the final decision / endorsement stage before the competent authority in DRAP, with all technical parameters and address variations cleared and approved. iii. That there has been zero change in the manufacturing lines, technical specifications, production plant, or ownership of the foreign manufacturer. Disqualifying a bona fide, compliant, and cost-effective bidder on account of an administrative address update that was fully valid on the tender date (11-08-2026), has since been fortified with fresh Apostilled certificates, and is already at the final decision stage before DRAP, is legally untenable and contrary to public interest.	

MOM OF GREIVANCE REDRESSAL COMMITTEE AGAINST TECHNICAL EVALUATION REPORT OF FRAMEWORK CONTRACT FOR THE PROCUREMENT OF MEDICAL DEVICES etc. FOR FY 2026-27

								E. ENTITLEMENT TO TOTAL RE-CALCULATED MARKS (INCREASE OF 11 MARKS) AND DECLARATION OF TECHNICAL RESPONSIVENESS: i. That the Applicant has already been awarded 19 marks under partial evaluation (including marks for ISO 9001, Bidder Experience, ERP System, and Financial Position). ii. That upon correcting the erroneous omissions by adding the legitimately earned and entitled eleven (11) marks: * Sole Agency / Bidder-Manufacturer Relationship (Above 2 to 5 Years): +08 Marks * Private Sector Sales Experience: +03 Marks * Total Lawfully Earned Marks to be Added: 08 + 03 = +11 Marks * Revised Aggregate Technical Score: 19 + 11 = 30 Marks (comfortably achieving the qualifying threshold of total marks). iii. That the Applicant has been confirmed compliant during physical verification.	

MOM OF GREIVANCE REDRESSAL COMMITTEE AGAINST TECHNICAL EVALUATION REPORT OF FRAMEWORK CONTRACT FOR THE PROCUREMENT OF MEDICAL DEVICES etc. FOR FY 2026-27

								The technical knockout criteria stand fully satisfied in letter and spirit. **Grievances of M/s Genome Pharma Regarding Wirah & Co.** 1. The firm's address on the Establishment Registration Certificate does not match the address stated in the enlistment certificate. 2. The firm's address on the Sale License does not match the address stated in the enlistment certificate. 3. The firm does not have the required duly verified or apostilled Sole Agency Agreement for the quoted item. 4. The firm's address on the Sole Agency Agreement does not match the address stated in the enlistment certificate. 5. The address on the sample does not match the address stated in the enlistment certificate. 6. The manufacturer's address on the ISO 13485 certificate does not match the	

MOM OF GREIVANCE REDRESSAL COMMITTEE AGAINST TECHNICAL EVALUATION REPORT OF FRAMEWORK CONTRACT FOR THE PROCUREMENT OF MEDICAL DEVICES etc. FOR FY 2026-27

								address stated in the enlistment certificate. 7. The manufacturer's address on the quality compliance certificate does not match the address stated in the enlistment certificate. 8. The brand name of the quoted product is not mentioned on the foreign manufacturer's registration certificate. 9. The name and address of the foreign manufacturer have not been verified by the relevant regulatory authority of the manufacturer's country.	
1	Blood Bags Sterile Packs 450/500ml single	S. Ejazuddin & Co.	JMS ELI-00078 MDIR No. 0000345 JMS Healthcare PHL, INC. Batangas Philippines JMS Blood Bag size 500ml sterile (single blood bag) master carton of 100's.	35	1. The attached Sole agency agreement is issued conditionally for DG Defence Purchase. 2. The undertakings regarding sub clause i, iv, vii & viii not as per the criteria. 3. The address & Name of Manufacturer on the attached Quality Certificate did not match with the one mentioned on sole	Compliant	Non-Responsive	Grievance Detail: has been conducted in accordance with the prescribed technical specifications, mandatory requirements, and evaluation criteria stated in the bidding documents. T.E. No Product Quoted Brand Name Objection Status Compliance Annexure 1 Blood Bag size 450/500ml sterile (single blood bag) master carton 100 or less JMS The attached Sole agency	Mr. M. Ateeq from M/s S. Ejazuddin & Co appeared before the GRC. The committee examined the grievance of the firm in the light of Advertised Evaluation Criteria and specifications along with Technical Evaluation Report. The committee after due deliberation decided as under: 1. The committee heard the stance of the firm regarding submitted sole agency

MOM OF GREIVANCE REDRESSAL COMMITTEE AGAINST TECHNICAL EVALUATION REPORT OF FRAMEWORK CONTRACT FOR THE PROCUREMENT OF MEDICAL DEVICES etc. FOR FY 2026-27

					agreement, DRC & ISO certificates. 4. The firm did not provide Registration of foreign manufacturer with regulatory authority of the country of manufacturer			agreement is issued conditionally for DG Defence Purchase. Not Responsive Relevant Documents attached A The undertakings regarding sub clause i, iv, vii & viii not as per the criteria. B The address & Name of Manufacturer on the attached Quality Certificate did not match with the one mentioned on sole agreement, DRC & ISO certificates C The firm did not provide Registration of foreign manufacturer with regulatory authority of the country of manufacturer D We regret for our negligence and thank you for giving us an opportunity to provide the missing documents. Thank you for your consideration. S. EJAZUDDIN & CO **Grievance of Wirha & Co against S. Ejazuddin & Co.** F. MATERIAL DEFICIENCY AND INELIGIBILITY OF M/S S. EJAZUDDIN & CO. (QUOTED BRAND: JMS, PHILIPPINES) – ABSENCE OF VALID CE MARK	agreement, which was issued conditionally for DG Defence Purchase, so it was not accepted. 2. The firm submitted the undertaking regarding sub clause i, iv, vii & viii as per the statement mentioned in evaluation criteria, which was accepted. 3. The firm could not furnish the Quality certificate for the quoted product bearing address & name of manufacturer similar to the one mentioned on sole agency agreement, Enlistment certificate and ISO certificates. 4. The firm could not furnish the Registration of foreign manufacturer with regulatory authority of the country of manufacturer for the quoted product. **Hence, the grievance of firm was liable to be rejected to the extent of 1, 3 & 4 parameters and the status of the quoted item remained Non-Responsive.**

MOM OF GREIVANCE REDRESSAL COMMITTEE AGAINST TECHNICAL EVALUATION REPORT OF FRAMEWORK CONTRACT FOR THE PROCUREMENT OF MEDICAL DEVICES etc. FOR FY 2026-27

								FOR DECLARED MANUFACTURING FACILITY: i. That M/s S. Ejazuddin & Co. quoted Blood Bags under Brand 'JMS', declaring the foreign manufacturing facility as M/s JMS Healthcare PHL, Inc., located in Batangas, Philippines. ii. That under the mandatory Compulsory Knockdown Criteria of the Bidding Documents, the bidder is legally bound to produce valid, authentic, and verifiable Quality Compliance Standards / CE Marking (CE MDD / MDR / US FDA 510K / WHO Prequalification) specifically certifying the quoted product and its declared manufacturing facility. iii. That it is a matter of verified technical record that the declared manufacturing plant in Batangas, Philippines possesses NO valid, recognized CE Mark certification for the quoted blood bags. The CE certification produced, if any, pertains to distinct	**Grievance of Wirha & Co against S.Ejazuddin & Co.** Representatives of M/s S. Ejazuddin & Co. & M/s Wirha & Co appeared before GRC and they were heard at length. The GRC decided that M/s S. Ejazuddin & Co was already declared non-responsive. So, there is no Locus Standi to proceed the grievance of M/s Wirha & Co. against M/s S. Ejazuddin & Co. **Grievance of M/s Genome Pharma against S. Ejazuddin & Co.:** Representatives of M/s S. Ejazuddin & Co. & M/s Genome Pharma attended the meeting. Grievance redressal committee heard the both parties in detail and decided that M/s S. Ejazuddin & Co was already declared non-responsive. So, there is no Locus Standi to proceed the grievance of M/s Genome Pharma against M/s S. Ejazuddin & Co.

								manufacturing sites/entities and does not cover the specific Batangas, Philippines production facility. iv. That furthermore, the address and name of the manufacturer appearing on their attached Quality Certificate did not match with the details stated on their Sole Agency Agreement, DRC, and ISO certificates. Coupled with the fact that their Sole Agency authorization was restricted/conditional for DG Defence Purchase and lacked mandatory foreign manufacturer registration, the offer of M/s S. Ejazuddin & Co. is fundamentally defective, non-compliant with compulsory knockdown criteria, and cannot be salvaged. **Grievance of M/s Genome Pharma against S. Ejazuddin & Co.:** The Sole Agency Agreement is not valid. 1. The manufacturer's name and address on the quality	

MOM OF GREIVANCE REDRESSAL COMMITTEE AGAINST TECHNICAL EVALUATION REPORT OF FRAMEWORK CONTRACT FOR THE PROCUREMENT OF MEDICAL DEVICES etc. FOR FY 2026-27

								certificate do not match the details stated in the Sole Agency Agreement, Drug Registration Certificate (DRC), and ISO certificates. 2. The firm does not have the required registration certificate for the quoted product issued by the regulatory authority of the foreign manufacturer's country.	
3	Nasogastric tube (all sizes)	United Healthcare Pvt Ltd	Starmed Bonree Medical Co., Ltd China Starmed feeding tube 1's, Sterile Individually packed. Size 5, 6, 8, 10FR MDIR-0008783 Starmed Stomach tube 1's, Sterile Individually packed. Size 12, 14, 16, 18, 20FR MDIR-0008784	35	1. The firm did not provide the sole agency agreement verified either by the Pakistan embassy in the country of origin or by the embassy of the country of origin in Pakistan or certified through apostille. 2. The firm did not provide Registration of foreign manufacturer with regulatory authority of the country of manufacturer 3. The firm quoted two different products having different enlistment numbers against the advertised item which is "Violation of PPR 2014 rule	Compliant	Non-Responsive	We acknowledge receipt of the Technical Evaluation Report for the Tender for Framework contract for the Procurement of Medical Devices etc. for the Financial Year of 2026-27. We would like to request clarification and reconsideration for the following item marked as non-compliant: 1. The valid Letter of Authorization (LOA) / Sole Agency Agreement is attached herewith, fully verified through an Apostille certification from the country of origin. 2. The foreign manufacturer (Bonree Medical Co., Ltd.) is officially registered with the	Mr. Awais Ahmad from M/s United Healthcare Pvt Ltd., appeared before the GRC. The committee examined the grievance of the firm in the light of Advertised Evaluation Criteria and specifications along with Technical Evaluation Report. The committee after due deliberation decided as under: 1. The firm provided the sole agency agreement certified through apostille, which was accepted. 2. The documents provided by the firm regarding registration of foreign manufacturer with regulatory authority of the country of manufacturer for

MOM OF GREIVANCE REDRESSAL COMMITTEE AGAINST TECHNICAL EVALUATION REPORT OF FRAMEWORK CONTRACT FOR THE PROCUREMENT OF MEDICAL DEVICES etc. FOR FY 2026-27

					no. 36A "One person one bid.			Guangdong Medical Products Administration (the regulatory authority of the country of manufacturer).The valid registration certificates were already provided in the original technical bid in the manufacturer's local language (Chinese)..The official Medical Device Registration Certificates are attached in English translation for the evaluation committee's review, proving active and valid regulatory compliance. 3.We are writing to formally submit our grievance against the observation/rejection of our technical bid under Rule 36A of the Punjab Procurement Rules 2014 (PPR 2014) – "One Person One Bid" concerning the advertised item "Nasogastric Tube All Sizes". We respectfully submit that our bid fully complies with Rule 36A, and the decision to reject it stems from a technical misinterpretation of the product range and regulatory	the quoted product was not verified from the website of the issuing authority. Hence, the grievance of the firm was rejected to the extent of this parameter. 3. The Committee heard the stance of firm at length, perused the documents and observed that the firm had quoted two different products having different enlistment numbers and different clinical implications against the quoted product which is in-fact the Violation of rule no. 36A of PPR-2014 "One person one bid". **Hence, the grievance of firm was not accepted to the extent of parameter 2 & 3 and the status of the quoted item remained Non-Responsive.**
4	Nelton Catheter	United Healthcare Pvt Ltd	Starmed Bonree Medical Co., Ltd China Starmed Nelaton cathetar 1's, Sterile Individually packed. Size 6, 8,	35	1. The firm did not provide the sole agency agreement verified either by the Pakistan embassy in the country of origin or by the embassy of the country of	Compliant	Non-Responsive		1. The firm provided the sole agency agreement certified through apostille, which was accepted. 2 Registration of foreign manufacturer with regulatory authority of the country of

			10, 12, 14, 16, 18, 20FR MDIR-0008782		origin in Pakistan or certified through apostille. 2. The firm did not provide Registration of foreign manufacturer with regulatory authority of the country of manufacturer			enlistments. We request a review based on the following facts: Key Grounds for Representation1. "All Sizes" Represents Distinct Medical Products The tender required Nasogastric Tubes (All Sizes), spanning 5Fr to 20Fr.Paediatric sizes (5Fr–10Fr) and Adult sizes (12Fr–20Fr) are distinctly different medical devices with separate lengths, thickness specifications, and clinical indications (paediatric vs. adult patient use).2. Regulatory Compliance with DRAP To strictly adhere to Drug Regulatory Authority of Pakistan (DRAP) regulations, distinct product lines require distinct enlistment numbers based on their physical and technical specifications: Sizes 5Fr, 6Fr, 8Fr, and 10Fr are registered under DRAP Enlistment No. MDIR-0008783.Sizes 12Fr, 14Fr, 16Fr, 18Fr, and 20Fr are registered under DRAP Enlistment No. MDIR-0008784.3. Full Compliance	manufacturer provided by the firm for the quoted product was not verified from the website of the issuing authority. **Hence, the grievance of firm was not accepted to the extent of this parameter. So, the status of the quoted item remained Non-Responsive.**

MOM OF GREIVANCE REDRESSAL COMMITTEE AGAINST TECHNICAL EVALUATION REPORT OF FRAMEWORK CONTRACT FOR THE PROCUREMENT OF MEDICAL DEVICES etc. FOR FY 2026-27

								with PPR 2014 Rule 36ARule 36A ("One Person One Bid") prevents a bidder from offering multiple alternative bids or competing options for the same individual item/size. No size was offered with two products: MDIR-0008783 was quoted exclusively for sizes 5Fr to 10Fr.MDIR-0008784 was quoted exclusively for sizes 12Fr to 20Fr.We have provided exactly one bid and one product per size category, fully satisfying the intent and legal requirement of Rule 36A.	

MoM- GRIEVANCES OF FIRMS AGAINST TER OF THE FRAMEWORK CONTRACT FOR THE PROCUREMENT OF BIOLOGICAL /BIO TECHNICAL ITEMS ETC. (FINANCIAL YEAR 2026-27)

Inq.	Generic Name	Quoted Brand Name	Company Name	Manufactured by	Final Status	Document Evaluation Remarks	Grievance of the Firm	Decision of The Committee
2.	Enoxaparin 6000IU /60mg/0.6ml Injection	Vinox 60mg MDIR: 115088	Lab Diagnostic Systems(SMC) Pvt. Ltd	Nanjing King Friend Biochemicals pharmaceutical Co., ltd China	Non-Responsive	1. Quality Compliance Standards (EMA/ JpMHLW/ US FDA/ prequalified by WHO (Certificate) of quoted item not attached.	With reference to the technical evaluation report of the subject tender, we respectfully submit this representation regarding the following quoted products of M/s Lab Diagnostic Systems (SMC) Pvt. Ltd.: · Enoxaparin Sodium Injection 60mg/0.6ml · Enoxaparin Sodium Injection 80mg/0.8ml manufactured by Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (China). As per the technical evaluation report, the quoted items were declared non-responsive under the observation that: "Quality Compliance Standards (EMA/JMHLW/US FDA/prequalified by WHO Certificate) of quoted item was not available." We respectfully clarify that the original US FDA ANDA approval letter (ANDA No. 206834), along with updated US FDA Certificates of a Pharmaceutical Product (COPPs) for both strengths, was duly submitted with our technical bid. According to our bid it is mentioned from Page # 33-37. The updated COPPs, issued on 15 July 2026 and valid until 15 July 2028, clearly confirm:	Mr. Ahmed Azeem from Lab Diagnostic Systems (SMC) Pvt. Ltd attended the meeting. The committee examined the grievance of the firm in the light of Advertised Evaluation Criteria and specifications along with Technical Evaluation Report. The committee after due deliberation decided that “The firm failed to provide Quality Compliance Standards (EMA/ JMHLW/ US FDA/ prequalified by WHO (Certificate) of quoted item as per requirement. The USFDA Standard mentioned enoxaparin 6000IU/ 60mg /0.6ml in the name of M/s Emerge Biosciences with market authorization. Whereas; the firm quoted brand Vinox but failed to produce quality certification for the quoted brand and COPP dually issued by Chinese regulatory authority

MoM- GRIEVANCES OF FIRMS AGAINST TER OF THE FRAMEWORK CONTRACT FOR THE PROCUREMENT OF BIOLOGICAL /BIO TECHNICAL ITEMS ETC. (FINANCIAL YEAR 2026-27)

							· US FDA approval under ANDA No. 206834 for both strengths. · Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (NKF), China, as the manufacturer. · Emerge Bioscience Pte. Ltd., Singapore, as the current Marketing Authorization Holder, consistent with the US FDA database. · Authorization for marketing in the United States. The submitted certificates are issued directly by the US FDA and are independently verifiable through the QR codes provided. For ease of verification and further clarification, copies of the relevant US FDA approval letter, updated COPPs and supporting documents are enclosed. We therefore respectfully request your good office to kindly reconsider the technical status of the quoted items in light of the enclosed clarification documents, as the quoted products fully comply with the tender requirement regarding US FDA approved products. We shall remain available for any further clarification or supporting documentation required by the authority.	(NMPA/Jiangsu MPA) specifically for the brand name vinox. **Hence grievance of the firm was liable to be rejected on this pretext to the extent of this parameter and status of the quoted item remained Non-Responsive.**
3.	Enoxaparin 8000IU /80mg/0.8ml Injection	Vinox 80mg MDIR: 115089	Lab Diagnostic Systems(SMC) Pvt. Ltd	Nanjing King Friend Biochemicals pharmaceutical Co., ltd China	Non-Responsive	1. Quality Compliance Standards (EMA/ JpMHLW/ US FDA/ prequalified by WHO (Certificate) of quoted item not attached.		Mr. Ahmed Azeem from Lab Diagnostic Systems (SMC) Pvt. Ltd attended the meeting. The committee examined the grievance of the firm in the light of Advertised Evaluation Criteria and specifications along with Technical Evaluation Report. The committee after due deliberation decided that "The firm failed to provide Quality Compliance Standards (EMA/ JMHLW/ US FDA/ prequalified by WHO (Certificate) of quoted item as per requirement. The USFDA Standard mentioned enoxaparin 8000IU/80mg /0.8ml in the name of M/s Emerge Biosciences with market authorization.

MoM- GRIEVANCES OF FIRMS AGAINST TER OF THE FRAMEWORK CONTRACT FOR THE PROCUREMENT OF BIOLOGICAL /BIO TECHNICAL ITEMS ETC. (FINANCIAL YEAR 2026-27)

								Whereas; the firm quoted brand Vinox but failed to produce quality certification for the quoted brand and COPP dually issued by Chinese regulatory authority (NMPA/Jiangsu MPA) specifically for the brand name vinox. **Hence grievance of the firm was liable to be rejected on this pretext to the extent of this parameter and status of the quoted item remained Non-Responsive.**